SCHEMBL12401769

SCHEMBL12401769

COc1c(Cl)cc(C(C)(C)C)cc1CN(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.53
CYP1A2 P05177 2/20 0.44
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
SLC6A4 P31645 9/20 0.38
HTR2A P28223 5/20 0.38
KCNH2 Q12809 4/20 0.38
CYP2D6 P10635 2/20 0.37
TSHR P16473 1/20 0.37
CYP2C9 P11712 1/20 0.36
HIF1A Q16665 1/20 0.36
SLC6A2 P23975 6/20 0.35
SLC6A3 Q01959 6/20 0.35
KMT2A Q03164 2/20 0.33
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
HTR2C P28335 1/20 0.33
HTR1E P28566 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104434 0.83 CYP2C19 (0.56) CYP2C19CYP1A2ALOX15MAPK1HTT
SCHEMBL1935976 0.81 CYP2C19 (0.53) CYP2C19CYP1A2ALOX15MAPK1HTT
SCHEMBL13458465 0.78 CYP2C19 (0.54) CYP2C19CYP1A2ALOX15MAPK1HTT
SCHEMBL13130527 0.78 CYP2C19 (0.50) CYP2C19CYP1A2ALOX15MAPK1HTT
SCHEMBL1936804 0.75 CYP2C19 (0.50) CYP2C19CYP1A2ALOX15MAPK1HTT
SCHEMBL5110866 0.75 CYP2C19 (0.50) CYP2C19CYP1A2ALOX15MAPK1HTT
SCHEMBL12404708 0.74 CYP1A2 (0.44) CYP2C19CYP1A2SLC6A4HTR2AKCNH2
SCHEMBL12401752 0.73 POLB (0.40) CYP2C19TSHRHTR1DHTR1BKDM4E
SCHEMBL12401768 0.72 CACNA1B (0.45) ALOX15MAPK1HTTTSHRCYP2C9
SCHEMBL7833966 0.72 ALDH1A1 (0.45) CYP2C19KMT2AKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372873-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-12 US disclosed
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-28 US disclosed
US-7964624-B1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES PRSS1, SPINT2, PRSS2 CYP2C19 1096/4885CYP1A2 1092/4885ALOX15 3225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.